Point72 Europe (London) LLP Intra Cellular Therapies, Inc. Transaction History
Point72 Europe (London) LLP
- $1.48 Billion
- Q3 2024
A detailed history of Point72 Europe (London) LLP transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Point72 Europe (London) LLP holds 19,385 shares of ITCI stock, worth $2.46 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
19,385
Previous 32,300
39.98%
Holding current value
$2.46 Million
Previous $2.21 Million
35.94%
% of portfolio
0.1%
Previous 0.2%
Shares
2 transactions
Others Institutions Holding ITCI
# of Institutions
382Shares Held
84.5MCall Options Held
319KPut Options Held
143K-
Vanguard Group Inc Valley Forge, PA9.63MShares$1.22 Billion0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$803 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.29MShares$672 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$489 Million1.4% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.05MShares$388 Million3.36% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $12B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...